ketotifen has been researched along with Allergic Conjunctivitis in 43 studies
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 9.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| "A group of 25 patients with signs of seasonal allergic conjunctivitis treated during the period of 2 to 6 month with ketotifen fumarate 0." | 9.11 | [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis]. ( Cerná, H; Haicl, P, 2004) |
| "The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0." | 9.10 | The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. ( Baena-Cagnani, CE; Berra, A; Gagliardi, J; Gallino, N; Gomez Demel, E; Mariani, AL; Martín, AP; Serra, HM; Urrets-Zavalia, E; Urrets-Zavalia, J, 2003) |
| " For the evaluation of itching, ovalbumin was used as an antigen instead of RW." | 7.75 | Cyclosporine A eye drops inhibit the early-phase reaction in a type-I allergic conjunctivitis model in mice. ( Katsuta, O; Nakamura, M; Oda, T; Shii, D; Shinomiya, K, 2009) |
| "To study the effects of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in guinea pigs and on ocular immediate hypersensitivity in albino rats." | 7.73 | Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat. ( Schoch, C, 2005) |
| "The effects of ketotifen and lodoxamide on eosinophil infiltration were assessed in a guinea pig model of allergic conjunctivitis." | 7.72 | Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. ( Schoch, C, 2003) |
| "Olopatadine hydrochloride controlled allergic conjunctivitis symptoms and signs more rapidly and to a greater extent than ketotifen fumarate." | 7.70 | Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. ( Aguilar, AJ, 2000) |
| "The effect of fenitrothion on experimental allergic conjunctivitis was studied using guinea pigs." | 7.69 | [Effect of fenitrothion on experimental allergic conjunctivitis]. ( Kato, H; Kishida, F; Kogiso, S; Nakamura, Y; Nakatsuka, I, 1996) |
| " The type and frequency of adverse events were similar across treatment groups." | 6.71 | Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. ( Cooper, C; Kidd, M; Lanz, R; McKenzie, SH; Steven, I, 2003) |
| " There were no significant differences in adverse events between groups." | 6.71 | Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. ( Abelson, MB; Casey, R; Dubiner, H; Greiner, JV; Kapik, BM; Lonsdale, J; Mundorf, T; Parver, L; Shams, NB, 2003) |
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 5.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| "The aim of this study was to compare short-term (5-minute) ocular comfort and drying effects of 3 topical antihistamine/mast cell stabilizers-epinastine, azelastine, and ketotifen-in patients with allergic conjunctivitis (AC)." | 5.13 | Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. ( Gomes, P; Ousler, GW; Torkildsen, GL, 2008) |
| "A group of 25 patients with signs of seasonal allergic conjunctivitis treated during the period of 2 to 6 month with ketotifen fumarate 0." | 5.11 | [Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis]. ( Cerná, H; Haicl, P, 2004) |
| "The efficacy and safety of ketotifen eye drop treatment in allergic conjunctivitis (AC) management is perfectly known by several studies, but the mechanism of action at the biochemical levels is poorly understood so we decided to perform an open, uncontrolled study in order to investigate the effect of the topical administration of ketotifen fumarate 0." | 5.10 | The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. ( Baena-Cagnani, CE; Berra, A; Gagliardi, J; Gallino, N; Gomez Demel, E; Mariani, AL; Martín, AP; Serra, HM; Urrets-Zavalia, E; Urrets-Zavalia, J, 2003) |
| "Ketotifen was safe and statistically effective in reducing ocular itching and hyperemia associated with allergic conjunctivitis." | 5.10 | Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. ( Abelson, MB; Chapin, MJ; Kapik, BM; Shams, NB, 2003) |
| "Ketotifen fumarate is a topical antiallergic combination mast-cell stabilizer and antihistamine indicated for the temporary prevention of ocular itching due to allergic conjunctivitis." | 5.10 | Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo ( Crampton, HJ, 2003) |
| "Topical olopatadine is a safe and effective treatment modality for allergic conjunctivitis, whereas alcaftadine appears to be superior to olopatadine in reducing ocular itch." | 4.95 | Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis. ( Chen, LJ; Kam, KW; Wat, N; Young, AL, 2017) |
| " For the evaluation of itching, ovalbumin was used as an antigen instead of RW." | 3.75 | Cyclosporine A eye drops inhibit the early-phase reaction in a type-I allergic conjunctivitis model in mice. ( Katsuta, O; Nakamura, M; Oda, T; Shii, D; Shinomiya, K, 2009) |
| "To study the effects of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in guinea pigs and on ocular immediate hypersensitivity in albino rats." | 3.73 | Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat. ( Schoch, C, 2005) |
| "The effects of ketotifen and lodoxamide on eosinophil infiltration were assessed in a guinea pig model of allergic conjunctivitis." | 3.72 | Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. ( Schoch, C, 2003) |
| "Olopatadine hydrochloride controlled allergic conjunctivitis symptoms and signs more rapidly and to a greater extent than ketotifen fumarate." | 3.70 | Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. ( Aguilar, AJ, 2000) |
| "The effect of fenitrothion on experimental allergic conjunctivitis was studied using guinea pigs." | 3.69 | [Effect of fenitrothion on experimental allergic conjunctivitis]. ( Kato, H; Kishida, F; Kogiso, S; Nakamura, Y; Nakatsuka, I, 1996) |
| "Nine patients with Japanese cedar pollinosis who had no nasal or ocular symptoms were included in the present study, after obtaining informed consent in writing." | 2.72 | Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen. ( Cheng, L; Dake, Y; Enomoto, K; Enomoto, T; Ikeda, H; Sakota, T; Shibano, A; Yajin, S; Yamanishi, E; Yoda, S, 2006) |
| "DSCG-chlorpheniramine was found to be more effective than ketotifen at preventing itching and redness in the CAC model." | 2.71 | The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model. ( Busca, F; Leonardi, A; Secchi, AG; Tavolato, M, 2003) |
| "Ketotifen-treated eyes experienced significantly less ocular itching induced by CAC than nedocromil-treated eyes and those that received placebo at both the 5-minute and 12-hour posttreatment allergen challenges (all P < 0." | 2.71 | A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model. ( Greiner, JV; Minno, G, 2003) |
| " The type and frequency of adverse events were similar across treatment groups." | 2.71 | Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. ( Cooper, C; Kidd, M; Lanz, R; McKenzie, SH; Steven, I, 2003) |
| " There were no significant differences in adverse events between groups." | 2.71 | Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis. ( Abelson, MB; Casey, R; Dubiner, H; Greiner, JV; Kapik, BM; Lonsdale, J; Mundorf, T; Parver, L; Shams, NB, 2003) |
| " No drug-related systemic adverse events were reported, and ocular adverse events were comparable to placebo." | 2.71 | Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population. ( Abelson, MB; Crampton, HJ; Ferzola, NJ; McWhirter, CL, 2004) |
| "Cetirizine was significantly more effective at reducing the mean rhinorrhea score compared with oxatomide for both weeks 8 and 12 (P < 0." | 2.70 | The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. ( Hsieh, JC; Lai, DS; Lee, HS; Lin, KL; Lue, KH, 2002) |
| "025% ophthalmic solution, when dosed ocularly, offered protecdon against the nasal signs and symptoms of acute allergic rhinoconjunctival reaction as induced by the CAC model." | 2.70 | A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model. ( Crampton, HJ, 2002) |
| "Allergic conjunctivitis is an IgE-mediated inflammatory of conjunctiva." | 2.49 | Immunomodulators for conjunctivitis. ( Pacharn, P; Vichyanond, P, 2013) |
| "Histamine release was not stimulated by AL-4943A at concentrations as high as 10 mM." | 1.29 | The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. ( Brady, MT; Gamache, DA; Graff, G; Lang, LS; Miller, ST; Parnell, D; Spellman, JM; Stephens, DJ; Weimer, LK; Yanni, JM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.33) | 18.7374 |
| 1990's | 3 (6.98) | 18.2507 |
| 2000's | 28 (65.12) | 29.6817 |
| 2010's | 8 (18.60) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Logan, A | 1 |
| Pucker, AD | 1 |
| Franklin, Q | 1 |
| McGwin, G | 1 |
| Hogan, C | 1 |
| Kelley, LR | 1 |
| Christensen, M | 1 |
| Brafford, R | 1 |
| Lievens, C | 1 |
| Romita, P | 1 |
| Stingeni, L | 1 |
| Barlusconi, C | 1 |
| Hansel, K | 1 |
| Foti, C | 1 |
| Ben-Eli, H | 1 |
| Solomon, A | 1 |
| Leonardi, A | 3 |
| Capobianco, D | 1 |
| Benedetti, N | 1 |
| Capobianco, A | 1 |
| Cavarzeran, F | 1 |
| Scalora, T | 1 |
| Modugno, R | 1 |
| Feuerman, OM | 1 |
| Boboridis, KG | 1 |
| Kozeis, N | 1 |
| Konstas, AG | 1 |
| Pall, B | 1 |
| Gomes, P | 2 |
| Yi, F | 1 |
| Torkildsen, G | 1 |
| Nabe, T | 1 |
| Kijitani, Y | 1 |
| Kitagawa, Y | 1 |
| Sakano, E | 1 |
| Ueno, T | 1 |
| Fujii, M | 1 |
| Nakao, S | 1 |
| Sakai, M | 1 |
| Takai, S | 1 |
| Pacharn, P | 1 |
| Vichyanond, P | 1 |
| Mortemousque, B | 1 |
| Bourcier, T | 1 |
| Khairallah, M | 1 |
| Messaoud, R | 1 |
| Brignole-Baudouin, F | 1 |
| Renault, D | 1 |
| Rebika, H | 1 |
| Brémond-Gignac, D | 1 |
| Kam, KW | 1 |
| Chen, LJ | 1 |
| Wat, N | 1 |
| Young, AL | 1 |
| Smets, K | 1 |
| Werbrouck, J | 1 |
| Goossens, A | 1 |
| Gilissen, L | 1 |
| Borazan, M | 1 |
| Karalezli, A | 1 |
| Akova, YA | 1 |
| Akman, A | 1 |
| Kiyici, H | 1 |
| Erbek, SS | 1 |
| Torkildsen, GL | 2 |
| Ousler, GW | 1 |
| Abelson, MB | 4 |
| Gomes, PJ | 1 |
| Shii, D | 1 |
| Oda, T | 2 |
| Shinomiya, K | 1 |
| Katsuta, O | 1 |
| Nakamura, M | 1 |
| Lambiase, A | 1 |
| Micera, A | 1 |
| Bonini, S | 1 |
| Lai, DS | 1 |
| Lue, KH | 1 |
| Hsieh, JC | 1 |
| Lin, KL | 1 |
| Lee, HS | 1 |
| Crampton, HJ | 3 |
| Martín, AP | 1 |
| Urrets-Zavalia, J | 1 |
| Berra, A | 1 |
| Mariani, AL | 1 |
| Gallino, N | 1 |
| Gomez Demel, E | 1 |
| Gagliardi, J | 1 |
| Baena-Cagnani, CE | 1 |
| Urrets-Zavalia, E | 1 |
| Serra, HM | 1 |
| Busca, F | 1 |
| Tavolato, M | 1 |
| Secchi, AG | 1 |
| Chapin, MJ | 1 |
| Kapik, BM | 2 |
| Shams, NB | 2 |
| Schoch, C | 2 |
| Greiner, JV | 2 |
| Minno, G | 1 |
| Lloves, J | 1 |
| Montero Iruzubieta, J | 1 |
| Sainz De La Maza Serra, MT | 1 |
| Fuster Jensen, E | 1 |
| Lladonosa Montull, A | 1 |
| Kato, M | 1 |
| Kurose, T | 1 |
| Miyaji, S | 1 |
| Kidd, M | 1 |
| McKenzie, SH | 1 |
| Steven, I | 1 |
| Cooper, C | 1 |
| Lanz, R | 1 |
| Mundorf, T | 1 |
| Dubiner, H | 1 |
| Lonsdale, J | 1 |
| Casey, R | 1 |
| Parver, L | 1 |
| Hashimoto, T | 1 |
| Igarashi, A | 1 |
| Hoshina, F | 1 |
| Yamada, M | 1 |
| Toyoda, Y | 1 |
| Notsu, Y | 1 |
| Kohno, S | 1 |
| Zafirakis, P | 1 |
| Haicl, P | 1 |
| Cerná, H | 1 |
| Ferzola, NJ | 1 |
| McWhirter, CL | 1 |
| Avunduk, AM | 1 |
| Tekelioglu, Y | 1 |
| Turk, A | 1 |
| Akyol, N | 1 |
| Dake, Y | 1 |
| Enomoto, T | 1 |
| Cheng, L | 1 |
| Enomoto, K | 1 |
| Shibano, A | 1 |
| Ikeda, H | 1 |
| Yoda, S | 1 |
| Yajin, S | 1 |
| Sakota, T | 1 |
| Yamanishi, E | 1 |
| Sanchis-Merino, ME | 1 |
| Montero, JA | 1 |
| Ruiz-Moreno, JM | 1 |
| Rodriguez, AE | 1 |
| Pastor, S | 1 |
| Yanni, JM | 1 |
| Stephens, DJ | 1 |
| Miller, ST | 1 |
| Weimer, LK | 1 |
| Graff, G | 1 |
| Parnell, D | 1 |
| Lang, LS | 1 |
| Spellman, JM | 1 |
| Brady, MT | 1 |
| Gamache, DA | 1 |
| Nakamura, Y | 1 |
| Kato, H | 1 |
| Kishida, F | 1 |
| Kogiso, S | 1 |
| Nakatsuka, I | 1 |
| Aguilar, AJ | 1 |
| Artal, MN | 1 |
| Luna, JD | 1 |
| Discepola, M | 1 |
| Morris, EC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis[NCT03186755] | Phase 4 | 42 participants (Anticipated) | Interventional | 2017-06-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for ketotifen and Allergic Conjunctivitis
| Article | Year |
|---|---|
Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Cromolyn S | 2018 |
Immunomodulators for conjunctivitis.
Topics: Administration, Sublingual; Animals; Conjunctivitis, Allergic; Cromolyn Sodium; Desensitization, Imm | 2013 |
Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
Topics: Administration, Ophthalmic; Anti-Allergic Agents; Benzazepines; Conjunctivitis, Allergic; Dibenzazep | 2017 |
Multiple action agents and the eye: do they really stabilize mast cells?
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Conjunctivitis, Allergic; Cytokines; Dibenzazep | 2009 |
Pharmacotherapy of allergic disease.
Topics: Adrenal Cortex Hormones; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Aged; Anaphylax | 1987 |
22 trials available for ketotifen and Allergic Conjunctivitis
| Article | Year |
|---|---|
Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops.
Topics: Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Drug Tolera | 2019 |
Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens.
Topics: Adolescent; Adult; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Contact Lenses; Drug Deliv | 2019 |
Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
Topics: Adult; Aged; Anti-Allergic Agents; Conjunctivitis, Allergic; Dibenzoxepins; Female; Humans; Ketotife | 2014 |
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
Topics: Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Child; Conjunctival Diseases; Conjunctiviti | 2009 |
Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study.
Topics: Adult; Conjunctivitis, Allergic; Cross-Over Studies; Dibenzazepines; Double-Blind Method; Female; Hi | 2008 |
Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
Topics: Adult; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Female; Human | 2008 |
The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis.
Topics: Allergens; Animals; Anti-Allergic Agents; Blood Proteins; Cetirizine; Child; Conjunctivitis, Allergi | 2002 |
A comparison of the relative clinical efficacy of a single dose of ketotifen fumarate 0.025% ophthalmic solution versus placebo in inhibiting the signs and symptoms of allergic rhinoconjunctivitis as induced by the conjunctival allergen challenge model.
Topics: Adult; Aged; Allergens; Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Female; | 2002 |
The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study.
Topics: Administration, Topical; Adolescent; Adult; Biomarkers; Chemokine CCL11; Chemokines, CC; Chemotactic | 2003 |
The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model.
Topics: Administration, Topical; Adolescent; Adult; Allergens; Anti-Allergic Agents; Chlorpheniramine; Conju | 2003 |
Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model.
Topics: Adult; Aged; Allergens; Anti-Allergic Agents; Conjunctiva; Conjunctivitis, Allergic; Double-Blind Me | 2003 |
Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo
Topics: Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Double-Bl | 2003 |
A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
Topics: Adolescent; Adult; Aged; Allergens; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Double-Bl | 2003 |
[Effectiveness and impact in the quality of life of ketotifen ophthalmic solution. Results of zeta study in patients with seasonal allergic conjunctivitis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allergens; Anti-Allergic Agents; Child; Conjunctivitis, | 2003 |
Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis.
Topics: Anti-Allergic Agents; Conjunctivitis, Allergic; Double-Blind Method; Female; Follow-Up Studies; Hist | 2003 |
Efficacy and safety of ketotifen fumarate 0.025% in the conjunctival antigen challenge model of ocular allergic conjunctivitis.
Topics: Adult; Aged; Allergens; Anti-Allergic Agents; Antigens; Conjunctiva; Conjunctivitis, Allergic; Doubl | 2003 |
Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Allergic Agents; Child; Choice Behavior; Conj | 2004 |
[Ketotifen fumarate (Zaditen) eye drops in the treatment of seasonal allergic conjunctivitis].
Topics: Adult; Anti-Allergic Agents; Conjunctivitis, Allergic; Female; Humans; Ketotifen; Male; Middle Aged; | 2004 |
Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
Topics: Adolescent; Anti-Allergic Agents; Child; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; | 2004 |
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
Topics: Adolescent; Adult; Anti-Allergic Agents; Cell Adhesion Molecules; Conjunctiva; Conjunctivitis, Aller | 2005 |
Effect of antihistamine eye drops on the conjunctival provocation test with Japanese cedar pollen allergen.
Topics: Adult; Allergens; Antigens, Plant; Conjunctivitis, Allergic; Cryptomeria; Dose-Response Relationship | 2006 |
A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
Topics: Choice Behavior; Conjunctiva; Conjunctivitis, Allergic; Dibenzoxepins; Double-Blind Method; Histamin | 2000 |
16 other studies available for ketotifen and Allergic Conjunctivitis
| Article | Year |
|---|---|
Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate.
Topics: Adolescent; Adult; Conjunctivitis, Allergic; Dibenzoxepins; Double-Blind Method; Female; Humans; Ket | 2023 |
Allergic contact dermatitis in response to ketotifen fumarate contained in eye drops.
Topics: Aged; Anti-Allergic Agents; Conjunctivitis, Allergic; Female; Humans; Ketotifen; Ophthalmic Solution | 2020 |
Revisiting Ocular Allergy: Evaluating Symptoms, Benzalkonium Chloride and Efficacy of Topical Ketotifen 0.025.
Topics: Benzalkonium Compounds; Conjunctivitis, Allergic; Humans; Ketotifen; Ophthalmic Solutions; Seasons | 2020 |
Involvement of chymase in allergic conjunctivitis of guinea pigs.
Topics: Allergens; Animals; Chymases; Conjunctivitis, Allergic; Disease Models, Animal; Enzyme Inhibitors; G | 2013 |
Sensitization from ketotifen fumarate in eye drops presenting as chronic conjunctivitis.
Topics: Adult; Anti-Allergic Agents; Chronic Disease; Conjunctivitis, Allergic; Female; Humans; Ketotifen; P | 2017 |
Cyclosporine A eye drops inhibit the early-phase reaction in a type-I allergic conjunctivitis model in mice.
Topics: Administration, Topical; Ambrosia; Animals; Anti-Allergic Agents; Betamethasone; Capillary Permeabil | 2009 |
Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis.
Topics: Administration, Topical; Animals; Anti-Allergic Agents; Cell Movement; Conjunctivitis, Allergic; Eos | 2003 |
The role of platelet activating factor and the efficacy of apafant ophthalmic solution in experimental allergic conjunctivitis.
Topics: Animals; Antigens; Azepines; Capillary Permeability; Conjunctivitis, Allergic; Disease Models, Anima | 2003 |
Effects of nonsteroidal anti-inflammatory drugs on experimental allergic conjunctivitis in Guinea pigs.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens; Benzophenones; | 2003 |
Effect of ketotifen fumarate, olopatadine, and levocabastine on ocular active anaphylaxis in the guinea pig and ocular immediate hypersensitivity in the albino rat.
Topics: Anaphylaxis; Animals; Capillary Permeability; Conjunctivitis, Allergic; Dibenzoxepins; Disease Model | 2005 |
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.
Topics: Animals; Anti-Allergic Agents; Benzimidazoles; Coloring Agents; Conjunctivitis, Allergic; Dibenzoxep | 2008 |
The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Topics: Administration, Topical; Anaphylaxis; Animals; Anti-Allergic Agents; Capillary Permeability; Conjunc | 1996 |
[Effect of fenitrothion on experimental allergic conjunctivitis].
Topics: Animals; Cholinesterase Inhibitors; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Feni | 1996 |
Rosiglitazone maleate. Ketotifen fumarate.
Topics: Conjunctivitis, Allergic; Diabetes Mellitus; Drug Administration Schedule; Histamine H1 Antagonists; | 1999 |
New drugs for allergic conjunctivitis.
Topics: Adult; Anti-Allergic Agents; Child; Child, Preschool; Clinical Trials as Topic; Conjunctivitis, Alle | 2000 |
Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
Topics: Adult; Aged; Conjunctivitis, Allergic; Dibenzoxepins; Female; Histamine H1 Antagonists; Humans; Keto | 2000 |